Xytex Expands Donor Screening to Include Hereditary Cancer Testing

EVANS, Ga., Oct. 5, 2026 /CourierPR/ -- Xytex, a leading provider of donor sperm, has expanded its donor screening protocol to include hereditary cancer genetic testing. This move reflects the company's commitment to staying at the forefront of genetic science and providing families with the most comprehensive information possible.

The expansion of the screening protocol was announced on behalf of Xytex by Mary Anna Hamilton, the company's President.

Xytex began pilot testing Natera's EmpowerTM hereditary cancer test in late 2025. The company evaluated the potential benefits of this advanced genetic testing and decided to integrate it into its donor screening process.

The new protocol applies to all new donor candidates since January 2026. The first qualified donors screened under the expanded protocol are expected to enter the Xytex donor website soon. This marks a significant step in the company's evolution, reflecting its history of adapting its practices alongside developments in reproductive medicine and genetic science. Founded in 1975, Xytex has helped people around the world build their families for more than 50 years. Xytex provides donor sperm supported by extensive donor screening, detailed donor information, and personalized client support.

Understanding hereditary cancer testing is crucial for families and their care teams. Unlike reproductive carrier screening, which evaluates genetic variants associated with inherited conditions that could be passed to a child, hereditary cancer testing evaluates certain inherited variants associated with an individual's predisposition to cancer. Xytex uses Natera's Empower hereditary cancer test as part of the expanded screening protocol. Empower is separate from the reproductive carrier screening performed by Natera's HorizonTM test and which is part of Xytex's donor screening process.

As donors screened under the expanded protocol become available, their hereditary cancer testing information will be included in their donor profiles for intended parents and care teams to consider as part of donor selection. Because donor qualification takes time, some donors who entered the Xytex screening process before hereditary cancer testing became part of the protocol in January 2026 will continue to enter the website without Empower testing. Those donors were accepted through Xytex's established screening process, and the addition of hereditary cancer testing does not change their qualification status.